Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,924 |
Ending reported balance
After 2026-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Grant · Acquired 943 · Balance 5,242 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-04 · Sale · Disposed 318 · Balance 4,924 F2: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 5, 2026 20:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 318 | $423.73 | $134,746.14 |
DisclosureSEC source: 0000875320-26-000175 · wk-form4_1778014276.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,924 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 943 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000175 · wk-form4_1778014276.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,242 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 266 | $500.00 | $133,000.00 |
DisclosureSEC source: 0000875320-26-000062 · wk-form4_1771449836.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,299 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 266 | $386.69 | $102,859.54 |
DisclosureSEC source: 0000875320-25-000222 · wk-form4_1756497726.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,565 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $505.86 | $202,344.00 |
DisclosureSEC source: 0000875320-25-000173 · wk-form4_1746476052.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,831 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 796 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000173 · wk-form4_1746476052.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,231 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 646 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · derivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 646 shares Expires 2028-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 646 | $500.00 | $323,000.00 |
DisclosureSEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,435 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 646 | $152.74 | $98,670.04 |
DisclosureSEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,292 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0000875320-24-000204 · wk-form4_1723493293.xml · derivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 646 Underlying: Common Stock · 1,292 shares Expires 2028-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,292 | $466.29 | $602,446.68 |
DisclosureSEC source: 0000875320-24-000204 · wk-form4_1723493293.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,435 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,292 | $152.74 | $197,340.08 |
DisclosureSEC source: 0000875320-24-000204 · wk-form4_1723493293.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 467 | $402.95 | $188,177.65 |
DisclosureSEC source: 0000875320-24-000117 · wk-form4_1714766716.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,435 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000117 · wk-form4_1714766716.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,902 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 243 | $375.00 | $91,125.00 |
DisclosureSEC source: 0001209191-23-053175 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,901 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023. Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 242 | $360.00 | $87,120.00 |
DisclosureSEC source: 0001209191-23-052622 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,144 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 242 | $345.51 | $83,613.42 |
DisclosureSEC source: 0000899243-23-018043 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,386 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 63 | $351.20 | $22,125.60 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,628 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $351.20 (range $350.92 to $351.48). Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 163 | $349.82 | $57,020.66 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,691 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $349.82 (range $349.17 to $350.08). Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $348.16 | $41,779.20 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,854 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $348.16 (range $347.91 to $348.64). Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 172 | $346.69 | $59,630.68 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,974 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $346.69 (range $346.31 to $347.03). Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 62 | $345.93 | $21,447.66 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,146 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $345.93 (range $345.20 to $346.12). Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,208 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 621 | $310.00 | $192,510.00 |
DisclosureSEC source: 0000899243-22-034249 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 47 | $295.53 | $13,889.91 |
DisclosureSEC source: 0000899243-22-028250 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,661 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 161 | $294.24 | $47,372.64 |
DisclosureSEC source: 0000899243-22-028250 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,708 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $294.24 (range $293.85 to $294.49). Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 204 | $293.15 | $59,802.60 |
DisclosureSEC source: 0000899243-22-028250 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,869 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $293.15 (range $292.71 to $293.61). Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 164 | $291.76 | $47,848.64 |
DisclosureSEC source: 0000899243-22-028250 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,073 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $291.76 (range $291.59 to $291.91). Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 45 | $290.18 | $13,058.10 |
DisclosureSEC source: 0000899243-22-028250 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $290.18 (range $290.05 to $290.20). Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5 | $282.34 | $1,411.70 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,282 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 58 | $281.03 | $16,299.74 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $281.03 (range $280.93 to $281.08). Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 99 | $280.22 | $27,741.78 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,345 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $280.22 (range $279.88 to $280.78). Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $279.28 | $44,684.80 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,444 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $279.28 (range $278.86 to $279.83). Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $277.95 | $55,590.00 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,604 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $277.95 (range $277.63 to $278.35). Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 99 | $276.65 | $27,388.35 |
DisclosureSEC source: 0000899243-22-027386 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $276.65 (range $276.21 to $276.83). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6 | $264.37 | $1,586.22 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 7 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,903 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 91 | $261.91 | $23,833.81 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,909 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $261.91 (range $261.69 to $262.09). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $260.82 | $20,865.60 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $260.82 (range $260.49 to $261.15). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $259.75 | $31,170.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $259.75 (range $259.35 to $260.14). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $258.90 | $31,068.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $258.90 (range $258.32 to $259.19). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 280 | $257.51 | $72,102.80 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,320 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $257.51 (range $257.15 to $258.09). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 40 | $255.40 | $10,216.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016337 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,640 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,907 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0000899243-22-014549 · doc4.xml · derivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,907 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,907 | $280.20 | $534,341.40 |
DisclosureSEC source: 0000899243-22-014549 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $280.20 (range $280.00 to $280.53). Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,907 | $125.71 | $239,728.97 |
DisclosureSEC source: 0000899243-22-014549 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 121 | $211.00 | $25,531.00 |
DisclosureSEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $211.00 (range $210.70 to $211.50). Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 153 | $210.01 | $32,131.53 |
DisclosureSEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,312 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $210.01 (range $209.64 to $210.34). Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 285 | $208.96 | $59,553.60 |
DisclosureSEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,465 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $208.96 (range $208.64 to $209.48). F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029837 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.